Castle Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSTL research report →
Range $35 – $44
Price Chart
About the company
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma.
- CEO
- Derek J. Maetzold
- IPO
- 2019
- Employees
- 1,002
- HQ
- Friendswood, TX, US
Get TickerSpark's AI analysis on CSTL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.01B
- P/E
- -42.70
- Fwd P/E
- 3622.53
- PEG
- 0.43
- P/S
- 2.69
- P/B
- 2.10
- EV/EBITDA
- -158.81
- Div Yield
- 0.00%
- Gross Margin
- 77.07%
- Op Margin
- -7.43%
- Net Margin
- -6.10%
- ROE
- -4.89%
- ROIC
- -5.42%
Latest fiscal year · YoY change
- Revenue
- $344.23M+3.7%
- Gross Profit
- $273.20M+0.5%
- Op Income
- $-42,810,000
- Net Income
- $-24,158,000-232.4%
- EPS
- $-0.83-225.8%
- OCF Growth
- -0.8%
- FCF Growth
- -22.5%
- 52W High
- $44.28
- 52W Low
- $17.72
- 50D MA
- $34.40
- 200D MA
- $28.09
- Beta
- 0.95
- RSI (14)
- 45
- Avg Volume
- 382.23K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Castle Biosciences posted 24% revenue growth, kept gross margin stable, and raised full-year revenue guidance on stronger TissueCypher and solid core business trends.· November 5, 2026
- Q3 revenue was $102.9 million, up 24% year over year, with TissueCypher test reports up 47%.
- Full-year 2026 revenue guidance was raised to $385 million-$395 million from $365 million-$375 million, reflecting continued TissueCypher strength and some ASP improvement.
- DecisionDx-Melanoma delivered 10,177 test reports and management now expects mid-single-digit full-year volume growth.
- TissueCypher remains early in penetration at about 15% of eligible procedures on a run-rate basis, and management sees room to grow.
- Gross margin held at 75% and adjusted gross margin stayed at 77%, while adjusted EBITDA was positive at $12.7 million.
- The company ended the quarter with about $278 million in cash, cash equivalents and marketable securities.
Castle reported Q3 2026 revenue of $102.9 million, up 24% versus Q3 2025. Gross margin was 75% compared with 75% a year ago, and adjusted gross margin was 77% versus 77% in the prior-year quarter. Net loss was $4.1 million, or $0.13 per diluted share, versus a net loss of $0.5 million, or $0.02 per diluted share, last year. Adjusted EBITDA was $12.7 million versus $9.2 million in Q3 2025, and net cash provided by operating activities was $19.7 million. The company raised full-year 2026 revenue guidance to $385 million-$395 million from $365 million-$375 million, said it still expects positive adjusted EBITDA in Q4 and for full-year 2026, and also expects full-year 2027 adjusted EBITDA to be positive absent a change in strategic direction.
Derek Maetzold framed the quarter as strong execution across the business, emphasizing disciplined expense management, clinical value, and continued momentum in the core portfolio. He highlighted TissueCypher’s growth, DecisionDx-Melanoma’s durable base, and new evidence publications supporting both TissueCypher and AdvanceAD-Tx. His tone was confident and constructive, with repeated comments that there is still significant room for growth and that the company is well positioned for 2027.
Frank Stokes focused on the financial quality of the quarter: revenue of $102.9 million, gross margin of 75%, adjusted gross margin of 77%, adjusted EBITDA of $12.7 million, and operating cash flow of $19.7 million. He noted the revenue guide increase to $385 million-$395 million was driven mainly by TissueCypher volume growth and, to a lesser extent, ASP improvement. He also walked through expense growth in sales and marketing, G&A, cost of sales, and R&D, and said the balance sheet ended at about $278 million in cash, cash equivalents and marketable securities, giving flexibility to invest in growth.
Analysts pressed on whether TissueCypher’s stronger-than-typical Q3 and implied Q4 strength reflected anything beyond the core business; management said it was mainly the core business and that the guidance already contemplates the current trend. Questions also focused on DecisionDx-Melanoma durability and management said there was nothing structural causing concern, with the company still on track for its volume outlook. On AdvanceAD-Tx pricing, management said CMS proposed gap fill instead of crosswalk, which surprised them, and they have submitted additional crosswalk data and expect the final recommendation later than usual, possibly in early December. Analysts also asked about SCC coverage timing, ASP durability, seasonality in TissueCypher, and sales force sizing; management said SCC recovery is assumed in 2028 planning, ASP gains look durable but are not heavily modeled for further upside, seasonality is normal, and both sales forces are around 100 or under 100 and sufficient for now.
The quarter showed broad-based operational momentum: revenue growth accelerated, TissueCypher volumes were strong, and DecisionDx-Melanoma remained above 10,000 reports for a fifth straight quarter. Management sounded confident that TissueCypher and the broader business still have room to expand, citing only about 15% penetration on a run-rate basis and expecting continued momentum through year-end and into 2027. The company also has a strong balance sheet and is already generating positive adjusted EBITDA and operating cash flow.
Some growth drivers remain dependent on payer and pricing outcomes, including ASP durability, Medicare coverage for DecisionDx-SCC, and CMS pricing for AdvanceAD-Tx. Management acknowledged quarterly lumpiness from seasonality and sales-force changes, especially in TissueCypher, which can make near-term performance uneven. The quarter also included a net loss and higher operating expenses, with labor and lab costs rising as volumes increase.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 89.2%
- Shares Outstanding
- 30.82M
- Float Shares
- 27.49M
of shares held by institutions
180 13F filers
Buy/sell ratio 0.12. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CSTL, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 3.45M | ▲ 161.75K |
| Rtw Investments, LP | 2.78M | 0 |
| Vanguard Group Inc | 2.20M | ▲ 27.51K |
| Principal Financial Group Inc | 1.50M | ▼ 225.75K |
| Portolan Capital Management, LLC | 1.37M | ▲ 1.04M |
| Vanguard Capital Management LLC | 1.24M | ▲ 11.45K |
| Acadian Asset Management LLC | 881.86K | ▼ 36.80K |
| State Street Corp | 804.68K | ▼ 17.40K |
| Geode Capital Management, LLC | 793.90K | ▼ 2.01K |
| Vanguard Portfolio Management LLC | 716.66K | ▼ 124.12K |
| Dimensional Fund Advisors LP | 692.10K | ▼ 98.98K |
| Jefferies Financial Group Inc. | 647.39K | 0 |
Held by 273 ETFs
Biggest fund positions in CSTL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | BRADBURY DANIEL | other | 5,985 |
| Nov 16, 26 | MAETZOLD DEREK J | sell | 1,396 |
| Nov 11, 26 | Juvenal Tobin W | other | 3,195 |
| Nov 11, 26 | Juvenal Tobin W | sell | 3,195 |
| Nov 11, 26 | Juvenal Tobin W | other | 3,195 |
| Nov 9, 26 | Juvenal Tobin W | sell | 3,288 |
| Nov 11, 26 | Juvenal Tobin W | sell | 2,828 |
| Nov 2, 26 | MAETZOLD DEREK J | sell | 7,555 |
| Nov 2, 26 | MAETZOLD DEREK J | sell | 1,025 |
| Nov 2, 26 | MAETZOLD DEREK J | sell | 2,816 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CSTL coverage
Recent articles, reports, and earnings notes.
No research on CSTL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CSTL report →Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture
prnewswire.com · Nov 12
Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference
prnewswire.com · Nov 11
DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging
prnewswire.com · Nov 11
Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 37%: Here's is How to Trade
zacks.com · Nov 10
What Castle Biosciences (CSTL) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
Castle Biosciences, Inc. (CSTL) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 5
Castle Biosciences Reports Third Quarter 2026 Results
prnewswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.